Scortichini Matteo, Mennini Francesco Saverio, Marcellusi Andrea, Paoletti Martina, Tomino Carlo, Sciattella Paolo
Economic Evaluation and Health Technology Assessment, Centre for Economic and International Studies, Faculty of Economics, University of Rome Tor Vergata, Rome, Italy.
Scientific Direction, IRCCS San Raffaele Roma, Rome, Italy.
Eur J Health Econ. 2024 Dec 18. doi: 10.1007/s10198-024-01736-5.
Asthma is a prevalent chronic respiratory condition that significantly impacts public health, with severe asthma subtypes, such as severe eosinophilic asthma, imposing substantial socioeconomic burdens.
Real-world data from the Italian Health Information System were analyzed to evaluate the economic consequences of asthma in Italy. An in-depth comparative analysis was conducted to investigate the economic implications of various asthma subtypes, focusing on severe eosinophilic asthma. Additionally, the study projected the potential cost-effectiveness of novel treatments aimed at reducing hospitalization rates, specialist visits, and oral corticosteroid use for patients with severe eosinophilic asthma in Italy.
The analysis revealed that severe asthma, and notably severe eosinophilic asthma, places a substantial economic burden on the Italian National Health System. Estimates demonstrated that implementing innovative treatments to mitigate the risks of hospitalization and specialist visits, as well as reducing oral corticosteroid usage in severe eosinophilic asthma patients, could lead to significant cost savings. The cost-consequence analysis indicated potential yearly reductions of €50.0 million (27%) for the treatment of severe asthma and €31.7 million (26%) for severe eosinophilic asthma.
This study presents a comprehensive evaluation of the economic repercussions of severe asthma in Italy. The findings emphasize the necessity of identifying and developing effective therapeutic strategies to improve the management of severe asthma while simultaneously reducing the economic burden on the healthcare system. These results offer valuable insights for healthcare policymakers and practitioners, facilitating evidence-based decisions in asthma management and healthcare policy in Italy.
哮喘是一种常见的慢性呼吸道疾病，对公众健康有重大影响，严重哮喘亚型，如严重嗜酸性粒细胞性哮喘，带来了巨大的社会经济负担。
分析来自意大利卫生信息系统的真实世界数据，以评估意大利哮喘的经济后果。进行了深入的比较分析，以调查各种哮喘亚型的经济影响，重点是严重嗜酸性粒细胞性哮喘。此外，该研究预测了旨在降低意大利严重嗜酸性粒细胞性哮喘患者住院率、专科就诊次数和口服糖皮质激素使用量的新型治疗方法的潜在成本效益。
分析表明，严重哮喘，尤其是严重嗜酸性粒细胞性哮喘，给意大利国家卫生系统带来了巨大的经济负担。估计显示，实施创新治疗以降低住院和专科就诊风险，以及减少严重嗜酸性粒细胞性哮喘患者的口服糖皮质激素使用量，可带来显著的成本节约。成本后果分析表明，治疗严重哮喘每年可能减少5000万欧元（27%），治疗严重嗜酸性粒细胞性哮喘每年可能减少3170万欧元（26%）。
本研究对意大利严重哮喘的经济影响进行了全面评估。研究结果强调了识别和制定有效治疗策略的必要性，以改善严重哮喘的管理，同时减轻医疗系统的经济负担。这些结果为医疗政策制定者和从业者提供了有价值的见解，有助于在意大利的哮喘管理和医疗政策中做出基于证据的决策。
